TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9765767

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (160 mg 3 times daily for 10 days)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Megestrol acetate
Number of subjects: 84
Study: 7812411

Group type: EXPERIMENTAL
Intervention: High 13C/12C ratio carbohydrates (corn, cane sugar, pineapple, millet)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low 13C/12C ratio carbohydrates
Number of subjects: 10
Study: 3057329

Group type: EXPERIMENTAL
Intervention: Bay 1099 (25, 50, or 100 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Bay 1099 (50 mg tid)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31166620

Group type: EXPERIMENTAL
Intervention: Nemolizumab 0.1 mg/kg every 4 weeks
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Nemolizumab 0.5 mg/kg every 4 weeks
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Nemolizumab 2.0 mg/kg every 4 weeks
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 28976791

Group type: EXPERIMENTAL
Intervention: Postoperative epirubicin, cisplatin, and infusional FU (ECF) before and after combined FU and radiotherapy
Number of subjects: 546

Group type: COMPARATOR
Intervention: Postoperative FU plus LV before and after combined FU and radiotherapy (FU plus LV arm)
Number of subjects: 546
Study: 26346429

Group type: EXPERIMENTAL
Intervention: Low-fat diet (LF diet)
Number of subjects: 897

Group type: COMPARATOR
Intervention: Mediterranean diet (MedDiet)
Number of subjects: 897
Study: 23567902

Group type: EXPERIMENTAL
Intervention: WISE intervention (motivational interviewing and cognitive behavioral therapy)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Control (education videos)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: WISE intervention
Number of subjects: 262

Group type: COMPARATOR
Intervention: Control
Number of subjects: 262
Study: 22043668

Group type: EXPERIMENTAL
Intervention: Deep puncture by elongated needle combined with spike-hooked needle and cupping
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional needling and cupping
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study: 19922576

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study: 17072268

Group type: EXPERIMENTAL
Intervention: TIVA with propofol and remifentanil
Number of subjects: 53

Group type: COMPARATOR
Intervention: Desflurane-fentanyl anesthesia
Number of subjects: 53
Study: 16215865

Group type: EXPERIMENTAL
Intervention: Behavioral intervention in intervention stores
Number of subjects: 560

Group type: COMPARATOR
Intervention: Control stores
Number of subjects: 560
Study: 12040433

Group type: EXPERIMENTAL
Intervention: Nucleoside analogues (NA) including fludarabine (FAMP) and cladribine (2‐CdA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination treatment with NA
Number of subjects: 0
Study: 9454993

Group type: EXPERIMENTAL
Intervention: PharmaCAL computer-assisted instruction package
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no exposure to PharmaCAL)
Number of subjects: 52
Study: 7591550

Group type: EXPERIMENTAL
Intervention: Cumulative meta-analysis of randomized control trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Routine use of meta-analysis on high-quality clinical data
Number of subjects: 0
Study: 2568643

Group type: EXPERIMENTAL
Intervention: procyclidine 5 mg t.i.d.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: promethazine 25 mg t.i.d.
Number of subjects: 33

Group type: COMPARATOR
Intervention: haloperidol 4.5 mg t.i.d. (group HPL)
Number of subjects: 33
Study: 785432

Group type: EXPERIMENTAL
Intervention: Carticain (Ultracain)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tetracain (Pantocain)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both Carticain and Tetracain
Number of subjects: 60
Study: 31176108

Group type: EXPERIMENTAL
Intervention: Open (high outcome expectancy)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo-controlled (low outcome expectancy)
Number of subjects: 23
Study: 27899529

Group type: EXPERIMENTAL
Intervention: rTFA (2% of daily energy intake from ruminant TFA)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: iTFA (2% of daily energy intake from industrial TFA)
Number of subjects: 142

Group type: COMPARATOR
Intervention: wTFA (diet without TFA)
Number of subjects: 142
Study: 26283145

Group type: EXPERIMENTAL
Intervention: Circumferential pulmonary vein ablation + linear ablation + complex fractionated atrial electrogram (CFAE) ablation
Number of subjects: 130

Group type: COMPARATOR
Intervention: Circumferential pulmonary vein ablation + linear ablation
Number of subjects: 130
Study: 23773796

Group type: EXPERIMENTAL
Intervention: Bevacizumab every 4 weeks
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Bevacizumab every 6 weeks
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Bevacizumab every 8 weeks
Number of subjects: 191
Study: 22214714

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg, thrice a day) for 4 weeks
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (10 μM) in vitro
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Vinpocetine (10 μM) in vitro
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Rolipram (10 μM) in vitro
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Isobutyl‐methylxanthine (IBMX, 100 μM) in vitro
Number of subjects: 83
Study: 19368965

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 200/6 microg twice daily plus as-needed
Number of subjects: 127

Group type: COMPARATOR
Intervention: Budesonide/formoterol 800/12 microg twice daily
Number of subjects: 127
Study: 16716321

Group type: EXPERIMENTAL
Intervention: Combination treatment of prednisone (20 mg/d), aspirin (100 mg/d), folate (5 mg every second day), and progesterone (20 mg/d) for the first 12 weeks of gestation.
Number of subjects: 80

Group type: COMPARATOR
Intervention: No treatment (control group).
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combination treatment of prednisone, aspirin, folate, and progesterone.
Number of subjects: 80
Study: 14760337

Group type: EXPERIMENTAL
Intervention: Das AngelWings device for closure of ASD or PFO
Number of subjects: 30
Study: 11325461

Group type: EXPERIMENTAL
Intervention: Negative mood state
Number of subjects: 60

Group type: COMPARATOR
Intervention: Positive mood state
Number of subjects: 60
Study: 9134638

Group type: EXPERIMENTAL
Intervention: Anti-factor VIII inhibitors (a-fVIII)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Lupus anticoagulants (LAs)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Change from a-fVIII to LA pattern
Number of subjects: 170
Study: 7934158

Group type: EXPERIMENTAL
Intervention: rhGM‐CSF with standard induction chemotherapy (TAD)
Number of subjects: 14
Study: 2849968

Group type: EXPERIMENTAL
Intervention: Pipecuronium 0.07 mg kg‐1
Number of subjects: 39

Group type: COMPARATOR
Intervention: Pancuronium 0.1 mg kg‐1
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Pipecuronium
Number of subjects: 39

Group type: COMPARATOR
Intervention: Pancuronium
Number of subjects: 39
Study: 29194612

Group type: EXPERIMENTAL
Intervention: Nanocurcumin therapy for 6 months
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nanocurcumin therapy
Number of subjects: 50
Study: 28753849

Group type: EXPERIMENTAL
Intervention: ODM-201 (200-1800mg, oral, twice daily)
Number of subjects: 134
Study: 25887096

Group type: EXPERIMENTAL
Intervention: Extended-release mixed amphetamine salts (60 mg)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Extended-release mixed amphetamine salts (80 mg)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 23694983

Group type: EXPERIMENTAL
Intervention: Perceived risk of cervical cancer
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: History of marriage
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Feeling adequately informed about cervical cancer by health care providers
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Intention to have cervical cancer screening in the future
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Willingness to undergo screening regardless of cost
Number of subjects: 388
Study: 21951433

Group type: EXPERIMENTAL
Intervention: Customized mindfulness training for eight weeks, followed by eight sessions of e-coaching and supporting elements (fruit and snack vegetables at the workplace, lunch walking routes, buddy system)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 0
Study: 18485309

Group type: EXPERIMENTAL
Intervention: Articaine 4% with adrenalin 1:200,000
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lidocaine 2% with adrenalin 1:100,000
Number of subjects: 50
Study: 17175661

Group type: EXPERIMENTAL
Intervention: Zemaira (study drug)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Prolastin (control drug)
Number of subjects: 44
Study: 12547873

Group type: EXPERIMENTAL
Intervention: HIM2 (0.5 mg/kg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: HIM2 (1.0 mg/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: HIM2 (0.5 and 1.0 mg/kg)
Number of subjects: 18
Study: 10883417

Group type: EXPERIMENTAL
Intervention: SKP-450 200 micrograms
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: SKP-450 300 micrograms
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: SKP-450 200 micrograms and 300 micrograms
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: SKP-450
Number of subjects: 28
Study: 8938913

Group type: EXPERIMENTAL
Intervention: Clozapine 200 mg/day (withdrawn abruptly)
Number of subjects: 30
Study: 1411636

Group type: EXPERIMENTAL
Intervention: 60 mg/m2 single oral dose on day 8
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 60 mg/m2 and 120 mg/m2 single oral doses on days 8 and 15
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 120 mg/m2 and 240 mg/m2 single oral doses on days 8 and 15
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 60 mg/m2 single oral doses on 5 consecutive days from days 8 to 12
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 50 mg/m2 three times a day at 6-hour intervals on day 8
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 240 mg/m2 single oral dose
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Multiple doses on 1 day or 5 consecutive days
Number of subjects: 25
Study: 3907642

Group type: EXPERIMENTAL
Intervention: Thymostimulin (TP‐1 Serono)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study: 30260551

Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic (SIL) surgery
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional laparoscopic (CL) surgery
Number of subjects: 50
Study: 30571332

Group type: EXPERIMENTAL
Intervention: Fish oil (eicosapentaenoic acid+docosahexaenoic acid; 8‐10 g for 2‐5 days preoperatively, and then 2 g/d postoperatively)
Number of subjects: 1516

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1516

Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 1516
Study: 27415448

Group type: EXPERIMENTAL
Intervention: Active monitoring
Number of subjects: 1643

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 1643

Group type: EXPERIMENTAL
Intervention: External-beam conformal radiotherapy
Number of subjects: 1643

Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 1643
Study: 25199624

Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT) screening
Number of subjects: 26722
Study: 22574800

Group type: EXPERIMENTAL
Intervention: Behaviour Therapy + Constructive Worry (BT + CW)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Behaviour Therapy (BT)
Number of subjects: 22
Study: 18801827

Group type: EXPERIMENTAL
Intervention: AVE1625 (20 mg)
Number of subjects: 0
Study: 18556965

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg twice daily for 6 months)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (twice daily for 6 months)
Number of subjects: 120
Study: 16087013

Group type: EXPERIMENTAL
Intervention: Single 2.0‐g dose of azithromycin microsphere formulation
Number of subjects: 507

Group type: COMPARATOR
Intervention: 10 days of levofloxacin, 500 mg/d
Number of subjects: 507
Study: 11937121

Group type: EXPERIMENTAL
Intervention: recombinant FSH (follitropin alpha)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: recombinant FSH (follitropin beta)
Number of subjects: 18

Group type: COMPARATOR
Intervention: urinary FSH
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: recombinant FSH (both types)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: recombinant FSH and urinary FSH
Number of subjects: 18
Study: 11577787

Group type: EXPERIMENTAL
Intervention: Optimized pharmacotherapy for GAD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Agent with demonstrated effectiveness for GAD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adequate dosing and duration of treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjunctive strategies for refractory patients
Number of subjects: 0
Study: 9164894

Group type: EXPERIMENTAL
Intervention: Episodes of ventricular fibrillation with intracardiac defibrillation
Number of subjects: 0

Group type: COMPARATOR
Intervention: External direct-current conversion of atrial fibrillation using high energies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pace-terminated ventricular tachycardia
Number of subjects: 0
Study: 8500243

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydralazine plus isosorbide dinitrate
Number of subjects: 0
Study: 3554886

Group type: EXPERIMENTAL
Intervention: Figure-of-eight bandage
Number of subjects: 79

Group type: COMPARATOR
Intervention: Simple sling
Number of subjects: 79
Study: 31972397

Group type: EXPERIMENTAL
Intervention: Creative music therapy (CMT)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 82
Study: 29574701

Group type: EXPERIMENTAL
Intervention: Adjunctive perampanel 12 mg
Number of subjects: 1218
Study: 27364955

Group type: EXPERIMENTAL
Intervention: 100 mg piragliatin twice daily
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 200 mg piragliatin twice daily
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: COMPARATOR
Intervention: 400 mg moxifloxacin
Number of subjects: 42
Study: 26573451

Group type: EXPERIMENTAL
Intervention: Yoga practice
Number of subjects: 39
Study: 23611405

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with docetaxel 40 mg/m² days 1 and 8 plus gemcitabine 1200 mg/m² days 1 and 8
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Consolidation chemotherapy with docetaxel 40 mg/m² days 1 and 8 plus gemcitabine 1200 mg/m² days 1 and 8
Number of subjects: 158

Group type: COMPARATOR
Intervention: Concurrent chemotherapy/radiotherapy (CT/TRT) with docetaxel 20 mg/m² and carboplatin AUC 2 weekly plus 60 Gy TRT
Number of subjects: 158

Group type: COMPARATOR
Intervention: Consolidation chemotherapy
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy and concurrent CT/TRT
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Consolidation chemotherapy and concurrent CT/TRT
Number of subjects: 158
Study: 21566289

Group type: EXPERIMENTAL
Intervention: Nickel titanium compression anastomosis clip
Number of subjects: 51

Group type: COMPARATOR
Intervention: Stapler
Number of subjects: 51
Study: 18287590

Group type: EXPERIMENTAL
Intervention: Carvedilol (32.9 +/- 3.5 mg)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Metoprolol succinate (96.4 +/- 15.9 mg)
Number of subjects: 37
Study: 17523575

Group type: EXPERIMENTAL
Intervention: Attentional Focus and Symptom Management Intervention (AFSMI)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 117
Study: 12943942

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 187

Group type: COMPARATOR
Intervention: HDRS score of 8
Number of subjects: 187

Group type: COMPARATOR
Intervention: MADRS score of 14
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: 60% reduction in HDRS and MADRS scores
Number of subjects: 187

Group type: COMPARATOR
Intervention: 50% reduction in HDRS and MADRS scores
Number of subjects: 187
Study: 11105738

Group type: EXPERIMENTAL
Intervention: 90 mg of enteric‐coated fluoxetine weekly
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: 20 mg of fluoxetine daily
Number of subjects: 501

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: 90 mg of enteric‐coated fluoxetine weekly and 20 mg daily fluoxetine
Number of subjects: 501
Study: 9196864

Group type: EXPERIMENTAL
Intervention: Iloprost (5-day infusion at 2.0 ng/kg per minute for 8 hours per day, followed by a 1-day infusion every 6 weeks)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Nifedipine (20 mg twice daily, oral slow-release formulation)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Iloprost
Number of subjects: 31
Study: 1343607

Group type: EXPERIMENTAL
Intervention: Online journals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Printed journals
Number of subjects: 0
Study: 30253405

Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg twice daily for 6 months post-VIU
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no medications)
Number of subjects: 60
Study: 28707034

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser photocoagulation
Number of subjects: 72

Group type: COMPARATOR
Intervention: Bipolar electrocautery
Number of subjects: 72
Study: 26286039

Group type: EXPERIMENTAL
Intervention: Training for occupational physicians to enhance adherence to mental health guidelines
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Higher baseline RTW self-efficacy scores
Number of subjects: 128
Study: 23520900

Group type: EXPERIMENTAL
Intervention: Prenatal counselling
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (no counselling)
Number of subjects: 86
Study: 21419609

Group type: EXPERIMENTAL
Intervention: Cystone(®)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 18667843

Group type: EXPERIMENTAL
Intervention: New bath oil containing St. John's wort extract
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Commercial bath oil 1
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Commercial bath oil 2
Number of subjects: 18

Group type: COMPARATOR
Intervention: 1% vol/vol sodium lauryl sulfate (SLS)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Distilled water (negative control)
Number of subjects: 18
Study: 16326163

Group type: EXPERIMENTAL
Intervention: Pamphlet based on the FDA Tips for the Savvy Supplement User
Number of subjects: 113

Group type: COMPARATOR
Intervention: Comparison group (not specified)
Number of subjects: 113
Study: 14671473

Group type: EXPERIMENTAL
Intervention: Individualized developmental care
Number of subjects: 92
Study: 11289500

Group type: COMPARATOR
Intervention: Warfarin therapy alone (average TT: 22.2%)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Warfarin therapy with antiplatelet agent (average TT: 20.9%)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Patients with thromboembolism (average TT: 26.4%, PT-INR: 1.53)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Patients without thromboembolism (average TT: 21.1%, PT-INR: 1.73)
Number of subjects: 170
Study: 9001879

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate (for non-responders from placebo)
Number of subjects: 30
Study: 1458789

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (3.6 g per day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 3881108

Group type: EXPERIMENTAL
Intervention: Aspirin 990 mg and dipyridamole 225 mg daily
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Aspirin and dipyridamole
Number of subjects: 320
Study: 31378215

Group type: EXPERIMENTAL
Intervention: CHIP-Family (n = 49)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Care as usual (n = 44)
Number of subjects: 93
Study: 30155910

Group type: EXPERIMENTAL
Intervention: Paternal psychological distress
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: Harsh discipline
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: Overinvolved parenting
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: Maternal mental health
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: Difficult child temperament
Number of subjects: 669
Study: 27198973

Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg
Number of subjects: 3066

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3066
Study: 24792139

Group type: EXPERIMENTAL
Intervention: Sustained natural apophyseal glides (SNAGs) with self-SNAG exercises
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Passive joint mobilization (PJM) with ROM exercises
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Sustained natural apophyseal glides (SNAGs)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Manual therapy (SNAGs and PJM)
Number of subjects: 86
Study: 22960461

Group type: EXPERIMENTAL
Intervention: 20% xylitol mouthrinse
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saccharine mouthrinse (control)
Number of subjects: 50
Study: 19661817

Group type: EXPERIMENTAL
Intervention: Transnasal EGD (T-EGD)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Conventional EGD without sedation (C-EGD)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Conventional EGD with sedation (CS-EGD)
Number of subjects: 300
Study: 16448280

Group type: EXPERIMENTAL
Intervention: Self-ligating brackets bonded with self-etching adhesive (3M Transbond Plus Self-etching primer)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Edgewise brackets bonded with conventional acid etching (Orthosolo primer and Enlight paste)
Number of subjects: 62